- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
BioCryst Pharmaceuticals (NASDAQ:BCRX), Quotes and News Summary
BioCryst Pharmaceuticals (NASDAQ: BCRX)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-04 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.370 | -0.400 | -0.0300 | ||||
| REV | 51.360M | 49.923M | -1.437M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
BioCryst Pharmaceuticals Questions & Answers
You can purchase shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) through any online brokerage.
Other companies in BioCryst Pharmaceuticals’s space includes: Twist Bioscience (NASDAQ:TWST), Sage Therapeutics (NASDAQ:SAGE), Fate Therapeutics (NASDAQ:FATE), Xencor (NASDAQ:XNCR) and ChemoCentryx (NASDAQ:CCXI).
The latest price target for BioCryst Pharmaceuticals (NASDAQ: BCRX) was reported by Barclays on Monday, April 18, 2022. The analyst firm set a price target for 13.00 expecting BCRX to rise to within 12 months (a possible 33.20% upside). 13 analyst firms have reported ratings in the last year.
The stock price for BioCryst Pharmaceuticals (NASDAQ: BCRX) is $9.76 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.